SCHEMBL2657010

SCHEMBL2657010

CCN1Cc2nc3c(-c4ccc(OC)cc4OC)c(F)ccc3c(N)c2C1=O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 6/20 0.51
▸ GABRB3 P28472 6/20 0.51
▸ GABRA2 P47869 6/20 0.51
▸ PDE5A O76074 5/20 0.43
▸ CRHR1 P34998 3/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ PDE6C P51160 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ METAP2 P50579 1/20 0.34
▸ CTSG P08311 1/20 0.33
▸ KLK7 P49862 1/20 0.33
▸ KLK14 Q9P0G3 1/20 0.33
▸ KLK5 Q9Y337 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661741 0.93 GABRG2 (0.51) GABRG2GABRB3GABRA2PDE5ACRHR1
SCHEMBL2660973 0.93 GABRG2 (0.52) GABRG2GABRB3GABRA2PDE5APDE6C
SCHEMBL2661405 0.93 GABRG2 (0.42) GABRG2GABRB3GABRA2PDE5AMETAP2
SCHEMBL2658808 0.92 GABRG2 (0.44) GABRG2GABRB3GABRA2PDE5APDE6C
SCHEMBL2656331 0.88 PDE5A (0.40) GABRG2GABRB3GABRA2PDE5AHSD17B10
SCHEMBL2655495 0.86 GABRG2 (0.43) GABRG2GABRB3GABRA2PDE5APDE6C
SCHEMBL2660050 0.86 PDE5A (0.39) GABRG2GABRB3GABRA2PDE5APDE6C
SCHEMBL2658370 0.85 PDE5A (0.47) GABRG2GABRB3GABRA2PDE5ALMNA
SCHEMBL2661947 0.85 CRHR1 (0.46) GABRG2GABRB3GABRA2PDE5ACRHR1
SCHEMBL2656082 0.85 GABRG2 (0.46) GABRG2GABRB3GABRA2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback